Kyverna Therapeutics, Inc. (KYTX) shareholders
Close on Nov 17, 2026Market cap $290.66MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| VV Manager LLC Joint filing with Vida Ventures, LLC (11.10%), Fred Cohen (10.50%) | 4,777,060 | 11.10% | 13D (active) | Feb 12, 2024 |
| Dr. Beth C. Seidenberg ("Seidenberg") Joint filing with Westlake BioPartners Fund I, L.P. ("Westlake Fund I") (6.30%), Westlake BioPartners GP I, LLC ("Westlake GP I") (6.30%) | 4,657,257 | 7.80% | 13G (passive) amendment | Dec 31, 2025 |
| Gilead Sciences, Inc. | 4,126,119 | 9.00% | 13G (passive) | Feb 12, 2024 |
| Orin Hirschman Joint filing with AIGH Capital Management LLC (5.90%) | 3,650,000 | 5.90% | 13G (passive) | Sep 30, 2026 |
| Michael P. Rubin | 3,466,826 | 6.10% | 13G (passive) amendment | Dec 31, 2025 |
| BlackRock, Inc. | 3,103,757 | 5.10% | 13G (passive) | Jun 30, 2026 |
| GordonMD Global Investments GP LLC Joint filing with GordonMD Global Investments LP (7.00%), Craig D. Gordon (7.00%) and 2 more | 3,058,485 | 7.00% | 13G (passive) | Nov 13, 2025 |
| JPMorgan Chase & Co. | 2,380,021 | 5.50% | 13G (passive) | Sep 30, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of KYTX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| GordonMD Global Investments LP | 4,244,818 | 6.86% | $37.82M | – | 18.30% |
| Gilead Sciences, Inc. | 4,126,119 | 6.67% | $36.76M | – | 2.23% |
| BlackRock, Inc. | 3,134,807 | 5.07% | $27.93M | +2,257,729 | 0.00% |
| Bain Capital Life Sciences Investors, LLC | 2,885,000 | 4.67% | $25.71M | −225,000 | 1.53% |
| AIGH Capital Management LLC | 2,795,797 | 4.52% | $24.91M | +795,797 | 1.57% |
| Deerfield Management Company, L.P. (Series C) | 2,000,000 | 3.23% | $17.82M | – | 0.19% |
| Vanguard Capital Management LLC | 1,897,451 | 3.07% | $16.91M | +114,109 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 1,186,023 | 1.92% | $10.57M | −369,264 | 0.00% |
| Geode Capital Management, LLC | 1,049,430 | 1.70% | $9.35M | +625,604 | 0.00% |
| Insight Holdings Group, LLC | 989,054 | 1.60% | $8.81M | – | 0.67% |
| Morgan Stanley | 982,307 | 1.59% | $8.75M | +5,018 | 0.00% |
| State Street Corp | 982,233 | 1.59% | $8.75M | +843,933 | 0.00% |
| Propel Bio Management, LLC | 883,198 | 1.43% | $7.87M | +238,777 | 4.12% |
| Woodline Partners LP | 845,325 | 1.37% | $7.53M | – | 0.02% |
| Millennium Management LLC | 639,780 | 1.03% | $5.70M | −365,728 | 0.00% |
| Mbb Public Markets I LLC | 614,477 | 0.99% | $5.47M | – | 0.59% |
| Adage Capital Partners Gp, L.L.C. | 500,000 | 0.81% | $4.46M | – | 0.01% |
| D. E. Shaw & Co., Inc. | 469,346 | 0.76% | $4.18M | −252,235 | 0.00% |
| Wells Fargo & Company/Mn | 373,009 | 0.60% | $3.32M | +258,610 | 0.00% |
| UBS Group AG | 365,574 | 0.59% | $3.26M | −84,176 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 120 | 38M | 60.8% | 31 / 36 | 28 / 21 | 8M | 5M |
| Q1 2026 | 111 | 35M | 56.3% | 27 / 31 | 35 / 14 | 7M | 4M |
| Q4 2025 | 99 | 34M | 55.2% | 36 / 29 | 21 / 9 | 18M | 2M |
| Q3 2025 | 75 | 23M | 36.7% | 10 / 18 | 29 / 14 | 1M | 2M |
| Q2 2025 | 79 | 23M | 37.5% | 16 / 29 | 24 / 24 | 2M | 5M |
| Q1 2025 | 87 | 26M | 41.7% | 15 / 26 | 25 / 15 | 2M | 5M |
| Q4 2024 | 88 | 29M | 46.7% | 23 / 32 | 14 / 28 | 8M | 6M |
| Q3 2024 | 94 | 31M | 49.4% | 28 / 24 | 22 / 21 | 4M | 6M |
| Q2 2024 | 88 | 34M | 55.0% | 28 / 33 | 13 / 30 | 10M | 8M |
| Q1 2024 | 90 | 32M | 51.4% | 90 / 0 | 0 / 0 | 32M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
92 funds held KYTX in Q2 2026, 68% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of KYTX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,403,697 | 2.27% | $12.51M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,073,618 | 1.74% | $9.57M | 0.01% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 856,798 | 1.39% | $7.63M | 0.06% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 458,351 | 0.74% | $3.35M | 0.01% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 448,147 | 0.72% | $3.99M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 352,088 | 0.57% | $3.14M | 0.02% | Jun 30, 2026 |
| iShares Biotechnology ETF | 266,211 | 0.43% | $2.37M | 0.03% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P Kensho New Economies Composite ETF | 260,625 | 0.42% | $2.32M | 0.08% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 183,789 | 0.30% | $1.57M | 0.00% | May 31, 2026 |
| Simplify Propel Opportunities ETF | 182,603 | 0.30% | $1.63M | 2.11% | Jun 30, 2026 |
| Nuveen Equity Index Fund | 177,936 | 0.29% | $1.30M | 0.00% | Jul 31, 2026 |
| Schwab U.S. Small-Cap ETF | 167,964 | 0.27% | $1.43M | 0.01% | May 31, 2026 |
| Invesco Dorsey Wright SmallCap Momentum ETF | 166,182 | 0.27% | $1.42M | 0.34% | May 31, 2026 |
| iShares Micro-Cap ETF | 139,400 | 0.23% | $1.24M | 0.08% | Jun 30, 2026 |
| Ultra-Small Company Fund | 112,000 | 0.18% | $997.92K | 1.01% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Christi Shaw | Executive Chairperson, Director | 66,741 | 0.11% | May 29, 2026 |
| Warner Weston Biddle | Chief Executive Officer, Director | 58,000 | 0.09% | Mar 17, 2026 |
| Gregory S. Martini | Chief Financial Officer | – | – | May 20, 2026 |
| Nadia Dac | Chief Commercial Officer | – | – | May 6, 2026 |
| Marc Grasso | Chief Financial Officer | 10,000 | 0.02% | Mar 17, 2026 |
| Naji Gehchan | See Remarks | 18,000 | 0.03% | Mar 17, 2026 |
| Mayobanex Pujols | Chief Technology Officer | – | – | Feb 11, 2026 |
| Karen Marie Walker | Chief Technology Officer | 22,636 | 0.04% | Dec 17, 2025 |
| Ryan Alexander Jones | Chief Financial Officer | 55,950 | 0.09% | Apr 15, 2025 |
| Fred E. Cohen | Director | 4,545,651 | 7.35% | May 29, 2026 |
| Beth C. Seidenberg | Director | 891,044 | 1.44% | May 29, 2026 |
| Ian T. Clark | Director | 21,727 | 0.04% | May 29, 2026 |
| Mert Aktar | Director | 21,727 | 0.04% | May 29, 2026 |
| Andrew Craig Miller | Director | 11,006 | 0.02% | Mar 4, 2026 |
| Sravan Kumar Emany | Director | 11,006 | 0.02% | Feb 26, 2026 |
| Daniel K. Spiegelman | Director | 16,634 | 0.03% | Jun 2, 2025 |
| Westlake BioPartners GP I, LLC | 10% owner | 735,984 | 1.19% | Dec 22, 2025 |
| Westlake BioPartners Opportunity GP I, LLC | 10% owner | – | – | Dec 22, 2025 |
| Westlake BioPartners Opportunity Fund I, L.P. | 10% owner | 869,317 | 1.41% | Dec 22, 2025 |
| Westlake BioPartners Fund I, L.P. | 10% owner | – | – | Dec 22, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Christi Shaw Executive Chairperson, Director | May 27, 2026 | Tax withholding | −4,194 | $8.59 | $36.03K | 66,741 |
| Beth C. Seidenberg Director | May 27, 2026 | Award | +5,093 | – | – | 21,727 |
| Ian T. Clark Director | May 27, 2026 | Award | +5,093 | – | – | 21,727 |
| Fred E. Cohen Director | May 27, 2026 | Award | +5,093 | – | – | 21,727 |
| Mert Aktar Director | May 27, 2026 | Award | +5,093 | – | – | 21,727 |
| Marc Grasso Chief Financial Officer | Mar 13, 2026 | Award | +10,000 | – | – | 10,000 |
| Naji Gehchan See Remarks | Mar 13, 2026 | Award | +18,000 | – | – | 18,000 |
| Warner Weston Biddle Chief Executive Officer, Director | Mar 13, 2026 | Award | +58,000 | – | – | 58,000 |
| Andrew Craig Miller Director | Feb 24, 2026 | Award | +11,006 | – | – | 11,006 |
| Sravan Kumar Emany Director | Feb 24, 2026 | Award | +11,006 | – | – | 11,006 |
| Christi Shaw Executive Chairperson, Director | Jan 12, 2026 | Award | +24,301 | – | – | 70,935 |
| Christi Shaw Executive Chairperson, Director | Jan 12, 2026 | Award | +30,000 | – | – | 46,634 |
| Westlake BioPartners Opportunity Fund I, L.P. 10% owner | Dec 18, 2025 | Buy | +133,333 | $7.50 | $1,000.00K | 869,317 |
| Beth C. Seidenberg Director | Dec 18, 2025 | Buy | +133,333 | $7.50 | $1,000.00K | 869,317 |
| Karen Marie Walker Chief Technology Officer | Dec 15, 2025 | Sale(10b5-1 plan) | −23,998 | $12.20 | $292.78K | 22,636 |
| Karen Marie Walker Chief Technology Officer | Dec 15, 2025 | Option exercise | +23,998 | $4.83 | $115.91K | 46,634 |
| Fred E. Cohen Director, 10% owner | May 29, 2025 | Award | +16,634 | – | – | 16,634 |
| Daniel K. Spiegelman Director | May 29, 2025 | Award | +16,634 | – | – | 16,634 |
| Ian T. Clark Director | May 29, 2025 | Award | +16,634 | – | – | 16,634 |
| Beth C. Seidenberg Director, 10% owner | May 29, 2025 | Award | +16,634 | – | – | 16,634 |
| Christi Shaw Director | May 29, 2025 | Award | +16,634 | – | – | 16,634 |
| Mert Aktar Director | May 29, 2025 | Award | +16,634 | – | – | 16,634 |
| Karen Marie Walker Chief Technology Officer | Apr 11, 2025 | Award | +13,000 | – | – | 22,636 |
| Ryan Alexander Jones Chief Financial Officer | Apr 11, 2025 | Award | +12,000 | – | – | 55,950 |
| Karen Marie Walker Chief Technology Officer | Jun 6, 2024 | Option exercise | +9,636 | $4.42 | $42.59K | 9,636 |
| Ryan Alexander Jones Chief Financial Officer | May 28, 2024 | Option exercise | +7,146 | $0.73 | $5.22K | 43,950 |
| Ryan Alexander Jones Chief Financial Officer | May 28, 2024 | Option exercise | +10,870 | $0.73 | $7.94K | 36,804 |
| Westlake BioPartners GP I, LLC 10% owner | Feb 12, 2024 | Conversion | +735,984 | – | – | 735,984 |
| Westlake BioPartners GP I, LLC 10% owner | Feb 12, 2024 | Conversion | +3,787,940 | – | – | 3,787,940 |
| Bain Capital Life Sciences Fund III, L.P. 10% owner | Feb 12, 2024 | Buy | +450,000 | $22.00 | $9.90M | 3,163,868 |
| Bain Capital Life Sciences Fund III, L.P. 10% owner | Feb 12, 2024 | Conversion | +2,713,868 | – | – | 2,713,868 |
| Beth C. Seidenberg Director, 10% owner | Feb 12, 2024 | Conversion | +735,984 | – | – | 735,984 |
| Beth C. Seidenberg Director, 10% owner | Feb 12, 2024 | Conversion | +3,787,940 | – | – | 3,787,940 |
| Vida Ventures GP III, L.L.C. 10% owner | Feb 12, 2024 | Buy | +583 | $22.00 | $12.83K | 583 |
| Vida Ventures GP III, L.L.C. 10% owner | Feb 12, 2024 | Buy | +252,553 | $22.00 | $5.56M | 252,553 |
| Vida Ventures GP III, L.L.C. 10% owner | Feb 12, 2024 | Conversion | +4,523,924 | – | – | 4,523,924 |
| Fred E. Cohen Director, 10% owner | Feb 12, 2024 | Conversion | +4,523,924 | – | – | 4,523,924 |
| Gilead Sciences, Inc. 10% owner | Feb 12, 2024 | Buy | +910,000 | $22.00 | $20.02M | 4,126,119 |
| Gilead Sciences, Inc. 10% owner | Feb 12, 2024 | Conversion | +3,216,119 | – | – | 3,216,119 |
| Northpond Ventures III GP, LLC – | Feb 12, 2024 | Conversion | +2,805,426 | – | – | 2,805,426 |
| Northpond Ventures III GP, LLC – | Feb 12, 2024 | Buy | +450,000 | $22.00 | $9.90M | 450,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Kyverna Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 16,927 shares on Sep 2, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Karen Marie Walker Officer | Apr 17, 2026 | 10,000 | $95.30K | Apr 17, 2026 | Exercise of Stock Options |
| Karen Marie Walker Officer | Apr 14, 2026 | 2,459 | $23.34K | Apr 14, 2026 | Restricted Stock Units |
| Daniel K. Spiegelman Director | Apr 7, 2026 | 17,578 | $162.64K | Apr 7, 2026 | Stock Option Exercise |
| Daniel K. Spiegelman Director | Mar 31, 2026 | 16,634 | $140.40K | Mar 31, 2026 | Restricted Stock |
| Karen Marie Walker Officer | Dec 15, 2025 | 23,998 | $210.70K | Dec 15, 2025 | Exercise of Stock Options |
See a number that looks wrong?